Autophagy: In the cROSshairs of cancer

详细信息    查看全文

• 作者：Heather Graham Hambright^a ; ^b ; Rita Ghosh^a ; ^b ; ^c ; ^d ; ^{ghoshr@uthscsa.edu}
• 关键词：Cancer ; Autophagy ; Cell fate ; Reactive oxygen species ; Therapy
• 刊名：Biochemical Pharmacology
• 出版年：2017
• 出版时间：15 February 2017
• 年：2017
• 卷：126
• 期：Complete
• 页码：13-22
• 全文大小：717 K
• 卷排序：126

文摘

Two prominent features of tumors that contribute to oncogenic survival signaling are redox disruption, or oxidative stress phenotype, and high autophagy signaling, making both phenomena ideal therapeutic targets. However, the relationship between redox disruption and autophagy signaling is not well characterized and the clinical impact of reactive oxygen species (ROS)-generating chemotherapeutics on autophagy merits immediate attention as autophagy largely contributes to chemotherapeutic resistance. In this commentary we focus on melanoma, using it as an example to provide clarity to current literature regarding the roles of autophagy and redox signaling which can be applicable to initiation and maintenance of most tumor types. Further, we address the crosstalk between ROS and autophagy signaling during pharmacological intervention and cell fate decisions. We attempt to elucidate the role of autophagy in regulating cell fate following treatment with ROS-generating agents in preclinical and clinical settings and discuss the emerging role of autophagy in cell fate decisions and as a cell death mechanism. We also address technical aspects of redox and autophagy evaluation in experimental design and data interpretation. Lastly, we present a provocative view of the clinical relevance, emerging challenges in dual targeting of redox and autophagy pathways for therapy, and the future directions to be addressed in order to advance both basic and translational aspects of this field.